Excluding a few small open-label studies and RCTs [62,63,64], therapies targeting the myostatin pathway have yielded inconclusive results in DMD [27,65] and other adult neuromuscular diseases [66,67,68]. Here, MSTN is linked to Duchenne muscular dystrophy.